Nausea Treatment Guidelines

First-Line Medications Based on Cause

The American College of Physicians recommends 5-HT3 receptor antagonists, such as ondansetron (4-8 mg) or granisetron (1 mg orally twice daily or 3.1 mg transdermal patch weekly), as first-line therapy for chemotherapy-induced nausea and vomiting 3, 4, 5
The National Comprehensive Cancer Network recommends adding dexamethasone (4 mg daily) to enhance antiemetic effect in patients with chemotherapy-induced nausea and vomiting 3, 4
For radiation-induced nausea and vomiting, the National Comprehensive Cancer Network suggests ondansetron (8 mg, 2-3 times daily) or granisetron (2 mg daily) for upper abdominal radiation 4, 6
For opioid-induced nausea, the National Comprehensive Cancer Network recommends prophylactic treatment with phenothiazines, such as prochlorperazine (5-10 mg every 6 hours), or dopamine antagonists, such as metoclopramide (10-20 mg) or haloperidol (0.5-1 mg) 2, 5, 8
For gastroparesis-related nausea, the American Gastroenterological Association recommends 5-HT3 antagonists, such as ondansetron (4-8 mg) or granisetron, and prokinetic agents, such as metoclopramide (5-20 mg three times daily) 5, 9

The American Society of Clinical Oncology recommends scopolamine transdermal patch (1.5 mg every 3 days) for motion sickness and vestibular-related nausea 1
The National Comprehensive Cancer Network suggests lorazepam (0.5-2 mg) or alprazolam (0.25-0.5 mg three times daily) for anticipatory nausea related to chemotherapy 3, 4, 6
For refractory nausea, the National Comprehensive Cancer Network recommends aprepitant (80 mg daily), especially in gastroparesis 5, 9
The American College of Physicians recommends dexamethasone (2-8 mg) for bowel obstruction or as adjunct to other antiemetics 1, 2

The National Comprehensive Cancer Network recommends behavioral therapy techniques, such as hypnosis with systematic desensitization and guided imagery, for anticipatory nausea 3, 4

For chronic nausea (≥4 weeks), the American Gastroenterological Association recommends comprehensive evaluation to determine underlying cause and target therapy based on gastric emptying status, with prokinetic agents, such as metoclopramide, for delayed emptying 5, 9
The National Comprehensive Cancer Network suggests combination therapy for refractory symptoms 2, 5

The American Society of Hematology warns that first-generation antihistamines and vasopressors should be avoided in infusion reactions as they may exacerbate hypotension and tachycardia 10
The American Gastroenterological Association notes that metoclopramide carries risk of extrapyramidal side effects, especially at higher doses 5
The National Comprehensive Cancer Network recommends reassessing cause and considering opioid rotation if opioid-induced nausea persists beyond 1 week 2